The Journal of Organic Chemistry
Article
reagents were used without further purification. The fluorescence
quantum yield (φ) was determined relative to quinine sulfate in 0.1 M
H2SO4 (λex 350 nm, λem 446 nm, φ 0.54).45 Starting materials 8-vinyl
adenosine44 and 8-Br-Adenosine,43 and analogues 5,28 6,28 7,55 and 828
were synthesized according to literature.
(74 mg, 0.34 mmol): mp 218 °C (dec); 1H NMR (300 MHz, DMSO-
d6) δ 8.12 (s, 1H), 7.99 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 8.4 Hz, 2H),
7.81 (d, J = 15.3 Hz, 1H), 7.73 (d, J = 15.3 Hz, 1H), 7.44 (s, 2H), 6.16
(d, J = 7.2 Hz, 1H), 5.82 (dd, J = 7.8 and 3.6 Hz, 1H), 5.36 (m, 1H),
5.27 (m, 1H), 4.73 (m, 1H), 4.21 (m, 1H), 4.03 (m, 1H), 3.87 (s, 3H),
3.77−3.60 (m, 2H) ppm; 13C NMR (75 MHz, DMSO-d6) δ165.9,
155.8, 152.1, 150.1, 147.6, 140.2, 134.7, 129.6, 129.5, 127.7, 119.3,
117.6, 87.5, 86.5, 72.8, 70.4, 61.8, 52.2 ppm; UV−vis (CH3OH) λmax
342 nm; HRMS (MALDI) m/z calcd for C20H22N5O6 [M + H]+
428.1565, found 428.1560.
DFT Calculations. To elucidate the absorption spectra of the 8-
(substituted cinnamyl)-adenosine analogues (SPEC), we performed
time-dependent density functional theory (TD-DFT) calculations.56
The M06-2X functional57 was employed, as it has been shown to
provide excellent agreement with experimental spectra.58 We note that
this global functional is most appropriate for valence and Rydberg
excitations, while somewhat less so for charge transfer processes.59 As
a comparison, the absorption spectra computed with the M06HF
functional is provided in Table S28 (Supporting Information). All
calculations were performed using the polarizable continuum model
solvent description modeling MeOH.60 The TD-DFT calculations
were performed using a 6-31+G (d,p) basis set or geometry
optimizations of the ground states, while single point calculations
used the 6-311++G(3df,2p) basis set.61 Electronic excitation spectra
calculated at the ground state optimized geometry correspond to the
absorption spectra. In addition to the absorption wavelengths,
oscillator strengths were computed, to provide information regarding
the intensity of the electronic transitions. All calculations used the
Gaussian 09 program.62
General Procedure for the Preparation of Analogues 9−11
and 14−17.42 A mixture of Pd(OAc)2 (4 mg, 0.02 mmol), P(o-tol)3
(10.2 mg, 0.03 mmol), Et3N (111 μL, 0.8 mmol), 8-vinyladenosine
(50 mg, 0.17 mmol), and aryl bromide/aryl iodide (0.34 mmol) in
DMF (2 mL) was prepared in an oven-dried vial, equipped with a
stirring bar, and was heated to 100−105 °C. Although the general
procedure described is for reactions on the 50 mg scale of 8-
vinyladenosine, some reactions were conducted at different scales, and
in these cases the proportions of reagents and solvents were
appropriately adjusted. Reactions were monitored by TLC, and
upon consumption of the starting material, the reaction mixtures were
diluted with EtOAc (40 mL) and washed with brine (20 mL) and
water (40 mL). The organic layer was separated, dried over Na2SO4,
and concentrated. The crude reaction products were purified by silica
gel column chromatography using DCM:MeOH (98:2−95:5) or
EtOAc:MeOH (98:2) as the eluent.
2-(6-Amino-8-(3-(trifluoromethyl)styryl)-9H-purin-9-yl)-5-
(hydroxymethyl)tetrahydrofuran-3,4-diol (14). Product 14 was
obtained as a light brown solid (56 mg, 47%), starting from 8-
vinyladenosine (80 mg, 0.27 mmol) and 3-bromobenzotrifluoride (123
mg, 0.54 mmol): mp 211 °C (dec); 1H NMR (600 MHz, DMSO-d6) δ
8.17 (s, 1H), 8.12 (s, 1H), 8.03 (d, J = 7.5 Hz, 1H), 7.81 (d, J = 15 Hz,
1H), 7.75 (d, J = 15 Hz, 1H), 7.71 (d,J = 7.5 Hz, 1H), 7.66 (t, J = 7.5
Hz, 1H), 7.41 (s, 2H), 6.17 (d, J = 7.2 Hz, 1H), 5.78 (dd, J = 8.4 and
4.2 Hz, 1H), 5.34 (d, J = 7.2 Hz, 1H), 5.22 (d, J = 4.8 Hz, 1H), 4.76
(q, J = 7.2 Hz, 1H), 4.22 (m, 1H), 4.03 (m, 1H), 3.73 (m, 1H), 3.63
(m, 1H) ppm; 13C NMR (150 MHz, DMSO-d6) δ 155.8, 152.0, 150.0,
147.7, 136.8, 134.6, 131.6, 130.1, 129.9, 129.7, 129.5, 126.8, 125.3,
125.3, 125.0, 123.8, 123.7, 123.2, 121.4, 119.3, 116.9, 87.7, 86.6, 72.7,
70.5, 61.9 ppm; UV−vis (CH3OH) λmax 334 nm; HRMS (MALDI)
m/z calcd for C19H18F3N5NaO4 [M + H]+ 460.1203, found 460.1230.
2-(6-Amino-8-(3-nitrostyryl)-9H-purin-9-yl)-5-(hydroxymethyl)-
tetrahydrofuran-3,4-diol (15). Product 15 was obtained as a brown
solid (20 mg, 18%), starting from 8-vinyladenosine (80 mg, 0.273
mmol) and 1-bromo-3-nitrobenzene (111 mg, 0.546 mmol): mp 188
°C (dec); 1H NMR (600 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.20 (d, J =
8.4 Hz, 2H), 8.12 (s, 1H), 7.85 (d, J = 16.2 Hz, 1H), 7.81 (d, J = 16.2
Hz, 1H), 7.71 (t, J = 8.4 Hz, 1H), 7.43 (s, 2H), 6.18 (d, J = 7.2 Hz,
1H), 5.79 (dd, J = 7.8 and 3.6 Hz, 1H), 5.35 (m, 1H), 5.25 (m, 1H),
4.76 (m, 1H), 4.21 (m, 1H), 4.04 (m, 1H), 3.74 (m, 1H), 3.63(m, 1H)
ppm; 13C NMR (150 MHz, DMSO-d6) δ 155.8, 152.1, 150.0, 148.5,
147.5, 137.5, 133.8, 130.3, 123.3, 121.7, 121.6, 119.3, 117.9, 87.7, 86.6,
72.7, 70.5, 61.9 ppm; UV−vis (CH3OH) λmax 335 nm; HRMS
(MALDI) m/z calcd for C18H18N6O6Na [M + Na]+ 437.1186, found
437.1184.
3-((E)-2-(6-Amino-9-(3,4-dihydroxy-5-(hydroxymethyl)-
tetrahydrofuran-2-yl)-9H-prin-8-yl)vinyl)benzonitrile (16). Product
16 was obtained as a brown solid (11 mg, 10%), starting from 8-
vinyladenosine (80 mg, 0.273 mmol) and 3-bromobenzonitrile (100
mg, 0.546 mmol): mp 177 °C; 1H NMR (600 MHz, DMSO-d6) δ 8.31
(s, 1H), 8.11 (s, 1H), 8.07 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 7.8 Hz,
1H), 7.74 (s, 2H), 7.63 (t, J = 7.8 Hz, 1H), 7.42 (s, 2H), 6.16 (d, J =
7.2 Hz, 1H), 5.81 (dd, J = 8.4 and 4.2 Hz, 1H), 5.32 (d, J = 6.6 Hz,
1H), 5.23 (d, J = 4.2 Hz, 1H), 4.75 (m, 1H), 4.22 (m, 1H), 4.03 (m,
1H), 3.73 (m, 1H), 3.63 (m, 1H) ppm; 13C NMR (150 MHz, DMSO-
d6) δ 155.8, 152.1, 150.0, 147.5, 136.9, 133.9, 132.2, 132.1, 130.7,
130.0, 119.3, 118.6, 117.3, 112.1, 87.7, 86.6, 72.7, 86.6, 72.7, 70.4, 61.9
ppm; UV−vis (CH3OH) λmax 337 nm; HRMS (MALDI) m/z calcd
for C19H19N6O4 [M + H]+ 395.1468, found 395.1475.
2-(6-Amino-8-(4-nitrostyryl)-9H-purin-9-yl)-5-(hydroxymethyl)-
tetrahydrofuran-3,4-diol (9). Product 9 was obtained as a dark brown
solid (20 mg, 28%), starting from 8-vinyladenosine (50 mg, 0.1706
mmol) and 4-bromonitrobenzene (69 mg, 0.34 mmol): mp 198 °C
(dec); 1H NMR (600 MHz, DMSO-d6) δ 8.25 (d, J = 9 Hz, 2H), 8.13
(s, 1H), 8.03 (d, J = 9 Hz, 2H), 7.84 (s, 2H), 7.46 (s, 2H), 6.17 (d, J =
7.2 Hz, 1H), 5.82 (dd, J = 7.8 and 3.6 Hz, 1H), 5.35 (d, J = 7.2 Hz,
1H), 5.26 (d, J = 4.8 Hz, 1H), 4.71 (q, J = 7.2 Hz, 1H), 4.21 (m, 1H),
4.04 (m, 1H), 3.74 (m, 1H), 3.64 (m, 1H) ppm; 13C NMR (150 MHz,
DMSO-d6) δ 155.9, 152.4, 150.2, 147.3, 147.1, 142.3, 133.6, 128.5,
124.1, 119.43, 119.40, 87.5, 86.5, 73.0, 70.4, 61.8 ppm; UV−vis
(CH3OH) λmax 367 nm; HRMS (MALDI) m/z calcd for C18H19N6O6
[M + H]+ 415.1361, found 415.1360.
4-((E)-2-(6-Amino-9-(3,4-dihydroxy-5-(hydroxymethyl)-
tetrahydrofuran-2-yl)-9H-purin-8-yl)vinyl)benzonitrile (10). Product
10 was obtained as a yellow solid (20 mg, 30%), starting from 8-
vinyladenosine (50 mg, 0.1706 mmol) and 4-iodobenzonitrile (78 mg,
4-((E)-2-(6-Amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-8-yl)vinyl)-2-
(trifluoromethyl)benzonitrile (17). Product 17 was obtained as a
yellow solid (55 mg, 35%), starting from 8-vinyladenosine (100 mg,
0.341 mmol) and 4-bromo-2-(trifluoromethyl)benzonitrile (171 mg,
1
0.34 mmol): mp 219 °C (dec); H NMR (200 MHz, DMSO-d6) δ
8.12 (s, 1H), 7.97 (d, J = 8.4 Hz, 2H), 7.87 (d, J = 8.4 Hz, 2H), 7.78
(s, 2H), 7.46 (s, 2H), 6.16 (d, J = 7.4 Hz, 1H), 5.82 (dd, J = 7.2 and
3.2 Hz, 1H), 5.35 (d, J = 7.2 Hz,1H), 5.25 (d, J = 4.4 Hz, 1H), 4.71
(m, 1H), 4.20 (m, 1H), 4.03 (m, 1H), 3.74−3.62 (m, 2H) ppm; 13C
NMR (75 MHz, DMSO-d6) δ 156.3, 152.7, 150.6, 147.9, 140.7, 134.7,
133.2, 128.7,119.8, 119.3, 119.0, 111.3, 88.1, 87.0, 73.3, 70.9, 62.3
ppm; UV−vis (CH3OH) λmax 350 nm; HRMS (MALDI) m/z calcd
for C19H19N6O4 [M + H]+ 395.1462, found 395.1470.
Methyl 4-((E)-2-(6-amino-9-(3,4-dihydroxy-5-(hydroxymethyl)-
tetrahydrofuran-2-yl)-9H-purin-8-yl)vinyl)benzoate (11). Product
11 was obtained as a brown solid (25 mg, 35%), starting from 8-
vinyladenosine (50 mg, 0.1706 mmol) and methyl 4-bromobenzoate
1
0.682 mmol): mp 236 °C (dec); H NMR (600 MHz, DMSO-d6) δ
8.42 (s, 1H), 8.22 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 7.8 Hz, 1H), 8.13
(s, 1H), 7.95 (d, J = 15.6 Hz, 1H), 7.85 (d, J = 15.6 Hz, 1H), 7.46 (s,
2H), 6.19 (d, J = 7.2 Hz, 1H), 5.77 (dd, J = 7.5 and 3 Hz, 1H), 5.34 (d,
J = 6.6 Hz, 1H), 5.24 (d, J = 4.2 Hz, 1H), 4.74 (m, 1H), 4.22 (m, 1H),
4.04 (m, 1H), 3.73(m, 1H), 3.64 (m, 1H) ppm; 13C NMR (150 MHz,
DMSO-d6) δ 156.0, 152.4, 150.1, 147.1, 141.1, 135.8, 132.9, 131.8,
131.5, 131.3, 131.1, 125.42, 125.39, 125.3, 123.5, 121.7, 120.4, 119.8,
119.5, 115.7, 87.7, 86.6, 72.9, 70.4, 61.9 ppm; UV−vis (CH3OH) λmax
356 nm; HRMS (MALDI) m/z calcd for C20H18N6O4F3 [M + H]+
463.1342, found 463.1345.
H
dx.doi.org/10.1021/jo402050x | J. Org. Chem. XXXX, XXX, XXX−XXX